Skip to main content
    T

    Trinity Biotech plc (TRIB)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $5.67
    -0.43 (-7.05%)

    Market Cap: $4.96M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Trinity Biotech plc (TRIB) Earnings: Report Dates and Results

    Updated Apr 30, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Trinity Biotech (TRIB) is expected to report earnings on Dec 22, 2026. In the quarter ended Mar 31, 2026, Trinity Biotech reported EPS of -$28.12. It beat the EPS estimate in 5 of the 8 most recent quarters that had an estimate.

    Earnings

    Performance (10Y)

    Beat Rate
    49%(17/35)
    Avg Surprise
    -13.08%

    Next Report

    TRIB has an expected report date of Dec 22, 2026.

    TRIB Earnings Call

    The latest TRIB earnings call transcript on file is labeled 2024Q3.

    Read the 2024Q3 transcript

    Earnings History

    Of the 37 quarters below that had an estimate, TRIB beat 18, missed 17 and matched 2. The widest gap in the table came in the quarter ended Sep 30, 2020, when EPS landed 258.00% above the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Mar 31, 2026-$28.12N/AN/AN/AN/AN/AN/AN/AApr 30, 2026$11.06M
    Dec 31, 2025-$0.90-$0.32N/A-181.25%MissN/AN/AN/AApr 30, 2026$11.06M
    Sep 30, 2025-$0.40N/AN/AN/AN/AN/AN/A0 up, 1 downDec 23, 2025$14.25M
    Jun 30, 2025-$14.40-$17.10N/A+15.79%BeatN/A10 up, 0 downJul 1, 2025$10.98M
    Mar 31, 2025-$1.24-$1.50N/A+17.42%BeatN/A10 up, 0 downMay 15, 2025$7.58M
    Dec 31, 2024-$26.35-$9.00N/A-192.75%MissN/A11 up, 0 downJan 29, 2025$15.86M
    Sep 30, 2024-$12.77-$16.20N/A+21.17%BeatN/A11 up, 0 downNov 15, 2024$15.15M
    Jun 30, 2024-$14.00-$19.50N/A+28.21%BeatN/AN/AN/AAug 13, 2024$15.84M
    Mar 31, 2024-$3.59-$3.60N/A+0.41%BeatN/AN/AN/AMay 22, 2024$14.70M
    Dec 31, 2023-$0.18-$0.14N/A-25.00%MissN/AN/A0 up, 0 downJan 31, 2024$14.70M
    Sep 30, 2023-$30.12-$13.50N/A-123.11%MissN/AN/A0 up, 0 downOct 3, 2023$14.68M
    Jun 30, 2023-$24.78-$9.00N/A-175.33%MissN/A10 up, 0 downJul 5, 2023$13.90M
    Mar 31, 2023-$0.06-$0.06-$0.06 - -$0.060.00%In lineN/A10 up, 0 downApr 10, 2023$14.83M
    Dec 31, 2022-$27.75-$9.00N/A-208.33%MissN/AN/A0 up, 0 downMar 23, 2023$18.04M
    Sep 30, 2022-$7.70-$6.00N/A-28.33%Miss-182.8%10 up, 0 downDec 15, 2022$18.04M
    Jun 30, 2022-$0.03-$0.03N/A0.00%In line-100.1%10 up, 0 downJul 21, 2022$18.46M
    Mar 31, 2022-$11.73-$6.00N/A-95.50%Miss-11830.0%10 up, 0 downApr 11, 2022$18.78M
    Dec 31, 2021-$0.06$0.07N/A-185.71%Miss-100.1%N/AN/AMar 23, 2022$19.52M
    Sep 30, 2021$9.30$12.00N/A-22.50%Miss-82.7%N/A0 up, 0 downDec 15, 2021$22.00M
    Jun 30, 2021$30.45$10.50N/A+190.00%BeatN/AN/A0 up, 0 downSep 9, 2021$25.84M
    Mar 31, 2021$0.10$0.07$0.07 - $0.07+42.86%Beat+88.7%1N/AMay 25, 2021$25.59M
    Dec 31, 2020$53.85$21.00N/A+156.43%Beat+298.9%1N/AMar 25, 2021$32.77M
    Sep 30, 2020$53.70$15.00N/A+258.00%Beat+7060.0%N/AN/ANov 17, 2020$32.01M
    Jun 30, 2020-$5.40-$0.02N/AN/AN/A-13600.0%N/AN/AAug 25, 2020$16.02M
    Mar 31, 2020$0.05$0.03N/A+76.67%Beat-92.9%N/AN/AMay 27, 2020$21.18M
    Dec 31, 2019$13.50$9.00N/A+50.00%Beat+19185.7%N/AN/AMar 31, 2020$21.32M
    Sep 30, 2019$0.75$9.00N/A-91.67%Miss-61.5%1N/AOct 16, 2019$24.59M
    Jun 30, 2019$0.04$0.07N/A-42.86%Miss-99.1%N/AN/AAug 20, 2019$22.50M
    Mar 31, 2019$0.75$10.50N/A-92.86%Miss-85.3%1N/AMay 7, 2019$22.03M
    Dec 31, 2018$0.07$0.04$0.04 - $0.04+75.00%Beat-12.5%1N/AMar 7, 2019$24.52M
    Sep 30, 2018$1.95$1.80N/A+8.33%Beat-80.2%1N/AOct 23, 2018$23.71M
    Jun 30, 2018$4.35$9.00N/A-51.67%Miss-6.5%1N/AJul 19, 2018$25.00M
    Mar 31, 2018$5.10$7.50$1.50 - $7.51-32.00%Miss+332.2%2N/AApr 20, 2018$23.80M
    Dec 31, 2017$0.08$0.07$0.07 - $0.07+14.29%Beat-63.6%1N/AMar 7, 2018$24.55M
    Sep 30, 2017$9.85$8.50N/A+15.88%Beat-27.0%2N/AOct 26, 2017$25.60M
    Jun 30, 2017$4.65$7.50$6.01 - $12.01-38.00%Miss-43.6%2N/AJul 20, 2017$25.45M
    Mar 31, 2017$1.18$0.90N/A+31.11%Beat-72.9%2N/AApr 27, 2017$23.54M
    Dec 31, 2016$0.22-$0.80N/A+127.50%Beat+100.0%N/AN/AMar 14, 2017$23.68M
    Sep 30, 2016$13.50$12.30N/A+9.76%Beat-7.2%N/AN/AOct 25, 2016$26.13M
    Jun 30, 2016$8.25$9.75N/A-15.38%Miss-44.4%N/AN/AJul 21, 2016$26.29M
    Last 40 quarters

    Estimates made before a stock split are shown on the same share basis as the reported EPS.

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$2.00, after -$56.71 the year before. It was $26.32 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$2.00N/A
    Dec 31, 2024-$56.71N/A
    Dec 31, 2023-$55.14N/A
    Dec 31, 2022-$47.21-218.6%
    Dec 31, 2021$39.79-61.1%
    Dec 31, 2020$102.20+579.5%
    Dec 31, 2019$15.04+31.1%
    Dec 31, 2018$11.47-27.2%
    Dec 31, 2017$15.76-40.1%
    Dec 31, 2016$26.32N/A

    Earnings Calls

    The 2 most recent earnings calls are listed below; the latest, 2024Q3 for the period ended Sep 30, 2024, runs about 5,200 words across 5 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2024Q3Sep 30, 20245,2195
    2024Q2Jun 30, 20245,0606

    2024Q3 Earnings Call

    Opening remarks

    Eric Ribner Investor Relations Thank you very much. Before we begin, please note that statements made during this presentation may be deemed forward-looking statements within the meaning of federal securities laws. These statements are subject to known and unknown risks and uncertainties that may cause actual events to differ from those expressed or implied in such statements. These risks include but are not limited to those set forth in the risk factor statements in the company's annual report on Form 20-F filed with the SEC. Trinity Biotech undertakes no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after today or the occurrence of unanticipated events. I will now hand the call over to John Gillard, President and CEO of Trinity Biotech, who will give an overview of Q2 performance and a business update. John will be followed by the company's Chief Financial Officer, Louise Tallon, who will give further details on third quarter financials. John, I'll turn it over to you.

    John Gillard President and CEO Good morning, everyone and thank you for joining today’s call. It has been an exciting time for our company. I have a lot to share with you today. Our company has been significantly transformed over the past year and we are now looking into the future and growth drivers that will create meaningful value for our shareholders. On our call today, I want to focus on three key elements. One, planning for long-term growth, which we believe will be driven by our continuous glucose monitor or CGM for diabetes management. As we progress towards the commercial launch of our next-generation solution, we are incredibly excited about the opportunity our innovative and pioneering approach presents in this fast market, a market that is already worth over $10 billion a year and projected to grow rapidly. In addition, in order to provide shareholders with more opportunities for value accretion, we are building out our pipeline of high-growth potential products through the acquisition of innovative prostate cancer and preeclampsia test technology, plus a strategic investment in a sepsis diagnostic technology. Moving on to two, I will also update you on our continued strong execution of our comprehensive transformation plan, which is establishing the profitability infrastructure for our existing and future business lines. This will support R&D for growth and balance sheet strengthening, as well as increasing the value of many of our existing business lines. And finally, three, I will speak to how we have strengthened the company by successfully addressing NASDAQ listing deficiencies, removing an important overhang from our stock. Before I address each of those three areas, let me first speak to our Q3 performance.

    Frequently Asked Questions About TRIB

    When is Trinity Biotech's next earnings date?

    Trinity Biotech's next earnings report is expected for Dec 22, 2026.

    How often does TRIB beat earnings estimates?

    Trinity Biotech beat the EPS estimate in 5 of the 8 most recent quarters that had an estimate, with an average surprise of -39.50%.